Open AccessDetection of measurable residual disease in adults with acute leukaemia
Author(s) -
Irina Galtseva,
Yulia Davydova,
Е Н Паровичникова
Publication year - 2020
Publication title -
gematologiâ i transfuziologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-3042
pISSN - 0234-5730
DOI - 10.35754/0234-5730-2020-65-4-460-472
Subject(s) - medicine , minimal residual disease , myeloid leukaemia , oncology , residual , disease , transplantation , haematopoiesis , clinical trial , leukemia , stem cell , algorithm , biology , computer science , genetics
. Measurable residual disease (MRD) is a residual amount of malignant cells able to invoke relapse after complete haematological remission. Aim . Analysis of the MRD prognostic value in various treatment protocols for acute leukaemia. Main ndings . MRD is a good prognostic indicator in lymphoblastic and myeloid leukaemia. Quantication of residual tumour cells is used for patient risk stratication according to the relapse prognosis. Stratication data, including MRD estimates at check points, may impact therapy choice, such as transplantation of allogeneic haematopoietic stem cells. Therefore, MRD estimation in acute leukaemia has become mandatory in clinical trial and research.